<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): SEPTEMBER 30, 1996
PHARMAGENICS, INC.
------------------------------------------------------
(Exact Name of Registrant as Specified in its Charter)
DELAWARE 0-20138 22-3072524
- ------------------------- ---------------- -------------------
(State or Other Juris- (Commission File (IRS Employer
diction of Incorporation) Number) Identification No.)
FOUR PEARL COURT
ALLENDALE, NJ 07401
-------------------- ----------
(Address of Principal (Zip Code)
Executive Offices)
(201) 818-1000
------------------------------------------------
(Registrant's Telephone Number, Including Area Code)
<PAGE>
ITEM 5. OTHER EVENTS
On September 30, 1996, William W. Crouse resigned as a director of the
Company as he had determined that he did not wish to stand for re-election at
the next Annual Meeting of Stockholders.
2
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the Registrant has duly caused this Report to be signed on its behalf
by the undersigned hereunto duly authorized.
PHARMAGENICS, INC.
/s/ A. Steven Franchak
-------------------------------------
Date: October 10, 1996 A. Steven Franchak
Vice President and Chief Financial Officer
